שולי רווח נקי: Myriad Genetics Corp (MYGN)

סמל מסחרי של Myriad Genetics Corp (MYGN)

Geopolitical tensions and reagent shortages are hindering the global research efforts of Myriad Genetics, Inc. (MYGN), as reflected in the company's net margin trends. The -16.10 level captures the current state of profitability. Business efficiency is driven by the expansion of software products and GeneSight alongside cost reductions. Stable working capital, achieved through the optimization of laboratories and hereditary testing, supports new R&D.

MYGN: שולי רווח נקי Myriad Genetics, Inc. 04.07.2022 - 19.11.2026

פילוחי נתונים אנליטיים מרוכזים עבור Myriad Genetics Corp (MYGN)

- שווי שוק ותחזית יעד של אנליסטים:
ניתוח ראשוני של החברה:Myriad Genetics Corp - MYGN
סחורת הדגל של Myriad Genetics Inc

Sales margins determine the share of net profit in every dollar of revenue, reflecting management's ability to convert income into final capital after deducting all expenses. By analyzing the net margin percentage, an investor can see the efficiency of the molecular diagnostics at Myriad Genetics, Inc. (MYGN), where growth in test volumes and cost optimization support operational resilience and the funding of new R&D projects.